DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993 – Biopharmaceutical Manufacturing
Preparedness Consortium
Notice is hereby given that, on April 12, 2024,
pursuant to section 6(a) of the National Cooperative
Research and Production Act of 1993, 15 U.S.C. 4301 et seq.
(“the Act”), Biopharmaceutical Manufacturing Preparedness
Consortium (“BIOMAP-CONSORTIUM”) has filed written
notifications simultaneously with the Attorney General and
the Federal Trade Commission disclosing changes in its
membership.

The notifications were filed for the purpose

of extending the Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages under specified
circumstances.
Specifically, A-line, Inc., Signal Hill, CA; API
Innovation Center, St. Louis, MO; AVS Bio, Norwich, CT;
Advanced Concept Innovations, Lakeland, FL; Afton
Scientific, Charlottesville, VA; Alchem Laboratories Corp.,
Alachua, FL; AmerStem, Inc., Camarillo, CA; American
Medicines Company, PBC, Davisville, WV; American Type
Culture Collection,

Manassas, VA; Amyris, Inc.,

Emeryville, CA; AntoXa Corp., Toronto, CANADA; Apertus
Pharmaceuticals LLC, Ballwin, MO; Argonaut Manufacturing
Services, Inc., Carlsbad, CA; Asha Therapeutics LLC, Tampa,

FL; Attogene Corp., Austin, TX; BASF Corp., Florham Park,
NJ; BCG Federal Corp., Washington, DC; BDO Public Sector
LLC, McLean, VA; Batavia Biosciences, Inc., Woburn, MA;
Benuvia Operations LLC, Round Rock, TX; Bionova Scientific
LLC, Fremont, CA; Biosortia Pharmaceuticals, Inc., Dublin,
OH; Black Mesa Technology, Inc., Bedford, MA; Blu Zone
Bioscience & Supply Chain Solutions, LLC, Frederick, MD;
Bracane Company, Inc., Plano, TX; CGCN, Washington, DC; CMC
Pharmaceuticals, Inc., Solon, OH; Capra Biosciences, Inc.,
Manassas, VA; ChromaTan, Inc., Lower Gwynedd, PA; Concept
to Market LLC, Monrovia, MD; Cornerstone Chemical Company,
Metairie, LA; Corning, Inc., Corning, NY; CuriRx, Inc.,
Wilmington, MA; DEKA Research & Development Corp.,
Manchester, NH; DMC Biotechnologies, Inc., Boulder, CO;
Dyadic International, Inc., Jupiter, FL; EriVan Bio,
Alachua, FL; EverGlade Consulting LLC, Houston, TX;
Evimero, Tuscaloosa, AL; FUJIFILM Diosynth Biotechnologies
USA, Inc., Morrisville, NC; Fisher BioServices, Inc.,
Rockville, MD; Foamtec International LLC, Waco, TX;
Fraunhofer USA, Plymouth, MI; HDT Bio Corp., Seattle, WA;
HERMES, LLC, Wilmington, NC; Health Blockchain Convergence,
Inc., Tysons Corner, VA; INTACT SOLUTIONS LLC, New Milford,
CT; InflaRx GmbH, Jena, GERMANY; Interbiome Partners LLC,
Rockville, MD; Jubilant HollisterStier CMO, Spokane, WA;
Kemp Proteins, Frederick, MD; LaCire LLC, Alexandria, VA;
Latham BioPharm Group, Elkridge, MD; MalarVx, Inc.,

Seattle, WA; Mallinckrodt Specialty Generics dba SpecGx
LLC, Webster Groves, MO; Manus Bio, Inc., Waltham, MA;
Medical Countermeasures Coalition, Washington, DC; Meissner
Filtration Products, Inc., Camarillo, CA; Michael Best
Strategies, Washington, DC; MilliporeSigma, Burlington, MA;
Nature's Toolbox, Inc., Rio Rancho, NM; New Horizon
Biotech, Inc., Nazareth, PA; NewAge Industries, Inc.,
Southampton, PA; Nipro PharmaPackaging Americas Corp.,
Millville, NJ; On Demand Pharmaceuticals, Inc., Rockville,
MD; PPD Development, L.P., Wilmington, NC; Par Sterile
Product LLC, Rochester, MI; PharmaJet, Golden, CO; Phlow
Corp., Richmond, VA; Prestige Ameritech, Ltd., North
Richland Hills, TX; ProQuality Network LLC, Dorado, PUERTO
RICO; Proteios Technology, Inc., Issaquah, WA; Quantum Four
Labs LLC, Arcadia, CA; SANARIA, Inc., Rockville, MD; SCHOTT
Pharma USA, Inc., Lebanon, PA; SK Pharmteco, Rancho
Cordova, CA; STERIS Corp., Mentor, OH; Scorpius
Biomanufacturing, Inc., San Antonio, TX; Sentio BioSciences
LLC, Maryland Heights, MO; Sepragen Corp., Union City, CA;
Shabas Solutions LLC, Fairfax, VA; Societal CDMO Inc.,
Gainesville, GA; Sotera Health Company, Broadview Heights,
OH; Southwest Research Institute, San Antonio, TX;
Strategic Marketing Innovations, Washington, DC; TEGA
Therapeutics, Inc., San Diego, CA; TFF Pharmaceuticals,
Inc., Fort Worth, TX; Tenagrity Solutions LLC, Fairfax, VA;
Texas A&M Engineering Experiment Station, Bryan, TX; Texas

Biomedical Research Institute, San Antonio, TX; Thaddeus
Medical Systems, Inc., Rochester, MN; The United States
Pharmacopeial Convention, Inc., Rockville, MD; Third Pole,
Inc., Waltham, MA; Tonix Pharmaceuticals Holding Corp.,
Chatham, NJ; TriLink BioTechnologies LLC, San Diego, CA; US
Specialty Formulations, Allentown, PA; University of
Delaware, Newark, DE; Vaxess Technologies, Inc., Cambridge,
MA; Wheeler Bio, Inc., Oklahoma City, OK; and Zalgen Labs
LLC, Frederick, MD, have been added as parties to this
venture.
No other changes have been made in either the
membership or planned activity of the group research
project.

Membership in this group research project remains

open, and the BIOMAP-CONSORTIUM intends to file additional
written notifications disclosing all changes in membership.
On January 5, 2024, the BIOMAP-CONSORTIUM filed its
original notification pursuant to section 6(a) of the Act.
The Department of Justice published a notice in the Federal
Register pursuant to section 6(b) of the Act on April 16,
2024 (89 FR 26923).
Suzanne Morris,
Deputy Director Civil Enforcement Operations,
Antitrust Division.

[FR Doc. 2024-13621 Filed: 6/20/2024 8:45 am; Publication Date: 6/21/2024]